drugset / Trial / NCT05566054
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
Phase 2
Recruiting
92 enrolled
The First Affiliated Hospital of Soochow University
Affiliated Hospital of Nantong University · collabJining Medical University · collabNorthern Jiangsu People's Hospital · collabSuzhou Hospital of Traditional Chinese Medicine · collabTaizhou University · collabThe First Affiliated Hospital of Bengbu Medical University · collabThe Second People's Hospital of Huai'an · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is to investigate the therapeutic efficacy and side effect of venetoclax, azacytidine combined with chidamide for newly diagnosed acute monocytic leukemia patients that are ineligible for intensive chemotherapy
Timeline
- Start
- 2022-03-01
- Primary completion
- 2026-09-30
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | — |
| Subject | Tucidinostat | Small molecule | 10 mg | Oral |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |